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Background: This study was performed to investigate on the genotypic frequencies 
of p53 Arg72Pro polymorphism and the prevalence of p53  codon 249 mutation in 
hepatocellular carcinoma patients.
Methods: Plasma DNAs were extracted from the samples of 44 early HCC cases, 
24 chronic B-viral hepatitis patients and 27 healthy individuals. Serum levels of 
AFP, PIVKA-II, and HBV DNA-positive rates among the study groups were also 
compared. PCR-based restriction fragment length polymorphism method was used 
to determine p53  Arg72Pro genotype and to detect codon 249 mutation.
Results: Serum AFP and PIVKA-II level, Edmondson grade, tumor size and 
frequency of HBV DNA-positivity among HCC group according to Arg72Pro 
genotypes showed no statistically significant difference. The frequencies of 
Arg72Pro genotypes (Arg/Arg, Arg/Pro, Pro/Pro) were respectively as follows: 
34.1%, 47.7%, 18.2% in HCC group; 29.2%, 54.2%, 16.7% in hepatitis group; 
29.6%, 55.6%, 14.8% in control group. Pro homozygote genotype had a higher 
risk for developing HCC by adjusted OR (1.529, 95% CI 0.325-7.193), but not 
statistically significant (P=0.591). No codon 249 mutation was found among 44 
HCC cases.
Conclusions: Pro homozygote was around 16% in all study groups, and did not 
statistically increase risks to developing HCC. We suggest that Arg72Pro 
polymorphism of p53  gene is not a significant risk factor in early 
hepatocarcinogenesis.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the 
most common malignancies, especially in Southeast 
Asia and South Africa [1]. Hepatocarcinogenesis is 
a complex, slow and multi-step process [2,3], and 
the etiologic agents of HCC are well known to be 
hepatitis B virus (HBV), hepatitis C virus and 
exposure to aflatoxin [1,4,5]. In addition, some 
genetic alterations were reported as potential risk 
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Table 1. Characteristics of study groups
 Variable
HCC Hepatitis Control P-value
 (N=44) (N=24) (N=27) HCC vs. hepatitis HCC vs. control
 Age (years)*
55.3 ± 10.6
(26 - 72)
46.9 ± 93.8
(24 - 62)
25.3 ± 1.3
(22 - 28)
0.0023 <0.0001
 Sex
 (Male/Female, N)
33/11 15/9 21/6 0.2797 0.7900
 AFP (IU/mL)*
3813.1 ± 8893.6 
(1.38 - 34089)
5.8 ± 5.0 
(1.12 - 17.79)
NT 0.0069
 HBV DNA positive,
 N/total tested (%)
10/36 (27.8) 18/24 (75.0) NT 0.0003 　
* Data are shown as 'mean ± SD (min - max)'.
All patients of HCC and hepatitis groups are HBsAg-positive and all individuals of control groups are HBsAg-negative.
Abbreviations: HCC, hepatocellular carcinoma; NT, not tested.
factors for HCC, and mutations or polymorphisms 
of p53 gene are one of the frequent genetic 
alterations accompanied with HCC [3]. p53 gene 
alterations were also investigated in some other 
human malignancies, and were associated with 
invasiveness, recurrence of cancer, or susceptibility 
to develop cancer in some studies [6-16]. 
However, the role of p53 polymorphisms in human 
carcinogenesis is still unclear and even con-
troversial in other study [17].
In the case of HCC, some ‘hot spots’ including 
exon 7 codon 249 mutation (Arg to Ser) and exon 
4 codon 72 polymorphism (Arg72Pro) of p53 gene 
were reported as risk factors for developing HCC 
[18-29]. Furthermore, p53 codon 249 mutation was 
reported to be associated with aflatoxin exposure 
[30-33], and incidences of mutation were reported 
to be variable according to the racial or geographic 
differences [18,20,26,27,34-39].
In this study, we investigated on the genotypic 
frequencies of p53 Arg72Pro polymorphism and the 
prevalence of p53 codon 249 mutation in early 
HCC patients to evaluate the role of p53 gene 
alterations in hepatocarcinogenesis. 
MATERIALS AND METHODS
1. Subjects and specimens
Blood samples from 44 early HCC patients with 
HBV infection who underwent hepatectomy (HCC 
group), 24 chronic B-viral hepatitis patients 
(hepatitis group) and 27 young healthy volunteers 
(control group) were collected. All patients in HCC 
and hepatitis groups were HBsAg-positive. 
Individuals in the control group were tested for 
complete blood counts, routine chemistries, liver 
enzymes and hepatitis viral markers, and no 
abnormal laboratory finding and past medical 
history were observed. Serum levels of 
alpha-fetoprotein (AFP) and protein induced by 
vitamin K absence or antagonist-II (PIVKA-II), 
and HBV DNA-positive rates in HCC and hepatitis 
groups were also evaluated. AFP levels were 
measured by using the UniCel DxI 800 Access 
Immunoassay system with Access AFP assay kits 
(Beckman Coulter GmbH, Krefeld, Germany). 
PIVKA-II concentrations were determined using 
Haicatch PIVKA-II enzyme-linked immunosorbent 
assay kits (Sanko Junyaku Co., Tokyo, Japan). 
HBV DNA was detected with Cobas Amplicor HCV 
monitor 2.0 assay (Roche Molecular Systems, Inc., 
Pleasanton, CA, USA). Edmondson grades and 
tumor sizes as the widest diameter in HCC group 
were analyzed by pathologist with liver tissues 
collected after hepatectomy.
2. Plasma DNA extraction
Plasma derived from blood samples anti-
coagulated with EDTA were processed immediately 
after collection and stored at -70℃ until used for 
DNA extraction. Cell-free DNA was extracted from 
140 μL of plasma using QIAcube with QIAamp 
viral RNA Mini Kit (QIAGEN GmbH, Hilden, 
Germany) which contains carrier RNA for 
enhancing DNA extraction yield.
3. Genotyping of p53 Arg72Pro polymorphism
The genotypes of Arg72Pro were determined by 
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Table 2. Characteristics of genotypic groups of p53 Arg72Pro in the HCC patients
 Variable Arg/Arg Arg/Pro Pro/Pro P-value† 
 AFP (IU/mL)*
2738.7 ± 8141.2
(4.0 - 30676.8) 
5430.7 ± 10665.4
(3.1 - 34089) 
1581.1 ± 3507.1
(1.4 - 10165.8) 
0.5030
 PIVKA-II (mAU/mL)*
423.4 ± 590.2
(20 - >2000)
327.2 ± 595.5
(11 - >2000)
600.5 ± 845.1
(15 - >2000)
0.0974
 Edmondson grade*
1.90 ± 0.54 
(I - III)
2.14 ± 0.50 
(I - III)
2.43 ± 0.53 
(II - III)
0.0899
 Tumor size (mm)*
41.3 ± 21.2
(16 - 95) 
40.6 ± 22.9
(10 - 80) 
59.3 ± 28.1
(35 - 114) 
0.2412
 HBV DNA positive,
 N/total tested (%)
4/10 (40.0) 5/19 (26.3) 1/7 (14.3) 0.4244
* Data are shown as 'mean ± SD (min - max)'.
† P-values were calculated by ANOVA tests.
Table 3. Genotypic frequencies of p53 Arg72Pro
Genotype HCC (N=44)
Hepatitis 
(N=24)
Control
(N=27)
Crude OR* Adjusted OR*,†
HCC vs.
non-HCC
HCC vs.
Hepatitis
HCC vs.
Control
HCC vs.
non-HCC
Arg/Arg, 
N (%) 15    (34.1) 7 (29.2) 8 (29.6) 1 1 1 1
Arg/Pro, 
N (%) 21 (47.7) 13 (54.2) 15 (55.6)
1.008 
(0.299-3.398)
0.892 
(0.258-3.083)
0.098 
(0.000-32.762)
1.008 
(0.299-3.398)
Pro/Pro, 
N (%) 8 (18.2) 4 (16.7) 4 (14.8)
1.237 
(0.570-2.682)
1.065 
(0.481-2.360)
0.634 
(0.009-45.075)
1.529 
(0.325-7.193)
* Data are shown as 'OR (95% confidence interval)'.
† Adjusted for age and sex.
Abbreviations: HCC, hepatocellular carcinoma; OR, odds ratio.
PCR-based restriction fragment length poly-
morphism (RFLP) method. Specific primers for 
PCR amplification of p53 gene exon4 were used 
(forward: 5’-TTGCCGTCCCAAGCAATGGATGA-3’, re-
verse: 5’-TCTGGGAAGGGACAGAAGATGAC-3’). PC
R thermo-cycling condition was 5 min at 94℃, 
followed by 40 cycles of 94℃ for 30 sec, 60℃ for 
40 sec, 72℃ for 40 sec, and with a final extension 
at 72℃ for 7 min. 20 μL of the reaction mixture 
included 6 μL of extracted DNA, each 1 μL of 
forward and reverse primers, 1.3 μL of form 
amide, and distilled water. 6-μL aliquots of PCR 
products were electrophoresed on 2% agarose gel 
for 25 min at 110 V to confirm the amplification 
of the target gene and the product DNA size was 
199 bp. Each 14 μL of remaining PCR products 
was digested with enzyme BstUI (New England 
BioLabs, Ipswich, MA, USA) at 37℃ for 2 hours 
and digested products were electrophoresed on 2% 
agarose gel for 30 min. Homozygotes for Pro were 
determined by the single 199 bp non-digested 
band, whereas homozygotes for Arg were 
represented by 113 and 86 bp sized bands. 
Heterozygote genotype was identified by 
representing combined pattern bands (86, 113 and 
199 bp) (Fig. 1).
4. p53 codon 249 mutation detection
p53 codon 249 mutation analysis was performed 
using PCR-based RFLP method. Primers for p53 
gene exon 7 were as follows; forward: 
5’-CTTGCCACAGGTCTCCCCAA-3’, reverse: 5’-AGGGG 
TCAGCGGCAAGCAGA-3’. Reaction condition was 5 
min at 94℃, followed by 40 cycles of 94℃ for 30 
sec, 58℃ for 30 sec, 72℃ for 30 sec, and with a 
final extension at 72℃ for 10 min. Target DNA 
amplification was confirmed as follows; 8-μL 
aliquot of the PCR product from 20-μL reaction 
mixture was loaded on 2% agarose gel to 
electrophorese for 25 min at 110 V. Remaining 
PCR products were digested with HaeIII for 
overnight at 37℃ and electrophoresed for 25 min 
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Fig. 1. Agarose gel electrophoresis of P53 Arg72Pro region PCR products. (a) Undigested PCR products with 199 bp in size, 
(b) PCR products digested with BstUI, 1: Arg/Arg homozygote, 2: Pro/Pro homozygote, 3: Arg/Pro heterozygote. 
100
500
200
bp
100
500
200
bp
(a) (b)
Fig. 2. Agarose gel electrophoresis of P53 exon 7 codon 249 region PCR products. (a) Undigested PCR products with 254 bp in 
size, (b) PCR products digested with HaeIII, all PCR products were cleaved to 92 and 66 bp fragments.
at 110 V. Non mutated codon 249 caused cleavage 
of 254-bp sized bands to 66 and 92 bp (Fig. 2). If 
there is AGG to AGT mutation at codon 249, 
uncleaved 158 bp fragment would be displayed. 
5. Statistical analysis
Characteristics of study groups were compared 
with T-test (for continuous variables) or 
chi-squired test (for categorical variables). ANOVA 
test was performed to compare genotypic 
differences of p53 Arg72Pro polymorphism among 
HCC group. Odds ratios (OR) for HCC and 95% 
confidence intervals (CI) were calculated using 
logistic regression with univariate and multivariate 
analysis, and age and sex were included as 
covariates for multivariate analysis. All statistical 
analyses were performed using SPSS 12.0 software 
(SPSS, Chicago, IL, USA), and a P-value less 
than 0.05 was considered as statistically 
significant.
RESULTS
There were 44 HCC and 51 non-HCC cases (24 
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hepatitis and 27 healthy control cases) in this 
study. Characteristics including age, sex, serum 
AFP level, HBV DNA positivity of study groups 
are shown in Table 1. The age (mean ± SD) of 
HCC, hepatitis and control groups were 55.3 ± 
10.6, 46.9 ± 93.8, 25.3 ± 1.3 years respectively, 
and they were significantly different (HCC vs. 
hepatitis, P=0.0023; HCC vs. control, P<0.0001). 
Serum AFP level of HCC group was higher than 
that of hepatitis group (P=0.0069) and the 
frequency of HBV DNA-positivity in the hepatitis 
group was higher than that in the HCC group 
(P=0.0003).
For the HCC group, serum AFP and PIVKA-II 
level, Edmondson grade, tumor size and frequency 
of HBV DNA-positivity among groups according to 
genotypes of Arg72Pro polymorphism are shown in 
Table 2, and no statistically significant difference 
between Arg72Pro genotypes was found.
Genotypic frequencies of p53 Arg72Pro, OR and 
95% CI for HCC are shown in Table 3. The 
frequencies of Arg72Pro genotypes were as follows: 
Arg/Arg 34.1%, Arg/Pro 47.7%, Pro/Pro 18.2% in 
HCC group; Arg/Arg 29.2%, Arg/Pro 54.2%, 
Pro/Pro 16.7% in hepatitis group; Arg/Arg 29.6%, 
Arg/Pro 55.6%, Pro/Pro 14.8% in control group. 
Pro homozygote genotype had a higher risk for 
HCC by crude OR (1.237, 95% CI 0.570-2.682) 
and adjusted OR (1.529, 95% CI 0.325-7.193) 
when HCC group was compared to non-HCC 
group, but no statistical significance was revealed 
(P=0.591 for crude and adjusted OR). 
PCR-based RFLP method was used to detect 
p53 exon 7 codon 249 mutation, and among 44 
HCC cases, no mutated exon 7 codon 249 was 
detected (Fig. 2). 
DISCUSSION
Hepatocarcinogenesis is a slow and complex 
process with multi-step stages and various risk 
factors including HBV, HCV infection, alcohol 
drinking, aflatoxin exposure, familial history and 
various genetic background [2,3]. Advances in 
molecular techniques have been made to reveal the 
carcinogenetic processes of some human 
malignancies, but genetic or epigenetic factors for 
developing HCC are still unclear. p53 gene is one 
of well-studied tumor suppressor genes.
HCC is the third most frequent malignancy in 
Korean male population, and the incidence rate of 
HCC in Korea is about 50 cases/100,000 
person/year. HBV infection is more prevalent in 
Korea compared to western countries. From these 
backgrounds, we investigated the frequency or 
prevalence of p53 gene alterations in Korean 
population with early HCC or B viral hepatitis, or 
in good health.
Regarding Arg72Pro polymorphisms of p53 gene 
in HCC patients, some previous studies suggested 
that Pro homozygotes had higher relative risk of 
HCC than Arg homozygotes, and they reported the 
frequencies of Pro homozygotes as around 18% to 
52% in HCC cases and 12% to 44% in control 
cases [21,23,40]. In our study, the frequencies of 
Pro homozygote were around 16% in HCC, 
hepatitis and control groups, which are lower than 
those in other studies, and there was no 
statistically significant increase of risk to 
developing HCC in Pro homozygote cases compared 
to Arg homozygote cases. 
We limited HCC cases as patients with hepatitis 
B virus infections and as who underwent 
hepatectomy, which means the patients were 
operable and in the early stage of cancer, to 
evaluate the role of Arg72Pro polymorphism of p53 
gene in early HCC cases. According to another 
study on the same polymorphism in HCC cases, no 
correlation between HCC and the Arg72Pro 
genotypes was found when comparing the HBsAg-
positive HCC subgroup to control [19]. Although 
not regarding HCC, some studies concluded that 
there was no evidence of association between the 
Arg72Pro polymorphism and increased risk to 
develop cancer [14,17].
The frequencies of Arg72Pro genotypes in our 
study were different to those of other studies, and 
this could imply that there are racial or 
geographical variations in Arg72Pro polymorphism, 
and our study results support that there may be 
no or little role of this polymorphism in early 
hepatocarcinogenesis. 
In addition to Arg72Pro polymorphism of p53 
gene, we investigated the prevalence of p53 exon 7 
codon 249 mutation in early HCC patients. As 
previously mentioned, the prevalence of codon 249 
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mutation was reported to be variable and was 
known to be associated with aflatoxin exposure. 
We found no mutated gene among 44 HCC cases 
and this result is similar with those investigated 
by Shi et al., and low codon 249 mutation 
frequency was also reported by another 
investigators [38,39]. Consequently, our result 
suggests low aflatoxin exposure in Korean 
population.
On the other hand, the number of subjects 
enrolled in this study was restricted, and this 
could cause a limited statistical power. 
Beta-statistical errors, which mean errors causing 
to interpret actually significant results as 
non-significant, are generally related to the 
limited number of study subjects. Therefore, 
further studies with larger populations would help 
to define the exact status and nature of 
polymorphisms in our study. 
There is no single main genetic risk factor for 
HCC proven up to now, and p53 gene alteration 
may play important roles in hepatocarcinogenesis. 
However, the p53 alterations investigated in our 
study were not significantly associated with early 
hepatocarcinogenesis. Racial and geographical 
differences of populations should be also 
considered in further researches for proving the 
mechanisms of hepatocarcinogenesis. 
요 약 
배경: 본 연구는 간암 초기 환자에서의 p53 유전자 
Arg72Pro 다형성 및 codon 249 돌연변이의 빈도를 조사하
여 간암 발생과 이들 유전자 변이의 관계를 규명하고자 하
였다.
방법: 44명의 초기 간암, 24명의 만성 B형 간염, 27명의 
건강인으로부터 혈액을 채취하여 혈장 유리 DNA를 추출하
였다. 혈청 내 AFP, PIVKA-II, HBV DNA를 측정하여 각 
군별로 비교하였다. 제한절편길이다형성분석(RFLP)을 통하
여 p53 Arg72Pro 유전형과 exon 7 codon 249 돌연변이를 
검출하였다.
결과: 간암 환자에서 Arg72Pro 유전형에 따른 혈청 내 
AFP, PIVKA-II 농도, 간암의 크기와 Edmondson 등급 및 
HBV DNA 양성률은 통계적으로 차이가 없었다. Arg72Pro 
유전형(Arg/Arg, Arg/Pro, Pro/Pro)의 빈도는 각각 다음과 
같다: 간암군 34.1%, 47.7%, 18.2%; 만성 B형 간염군 29.2%, 
54.2%, 16.7%; 대조군 29.6%, 55.6%, 14.8%. Pro 동형접합체 
유전형은 비간암군과 비교하여 간암 발생 교차비가 높았으
나(crude OR=1.237, 95% CI=0.570-2.682, adjusted OR= 
1.529, 95% CI= 0.325-7.193) 통계적으로 유의하지 않았다
(P=0.591). 44명의 간암환자에서 codon 249 돌연변이는 발
견되지 않았다.
결론: 본 연구에서는 Pro 동형접합체 유전형이 모든 실
험 대상군에서 16% 내외로 비슷하게 분포하였으며, Pro 동
형접합체가 간암 발생의 위험도를 유의하게 증가시키지 않
아, 간암 발생의 주요 요인으로 작용하지 않을 것으로 생각
된다. 
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